Bone morphogenetic protein receptor (BMPR) (BMPR)

Bone morphogenetic protein receptors (BMPRs) are transmembrane serine/threonine kinases belonging to the transforming growth factor-beta (TGF-beta) superfamily, essential for regulating cell growth, differentiation, and development (UniProt: Q13873, P36894). These receptors are categorized into two groups, Type I (e.g., BMPR1A, ACVR1) and Type II (e.g., BMPR2, ACVR2A), which form a functional heterotetrameric complex upon binding to bone morphogenetic protein (BMP) ligands (StatPearls: NBK541071). Activation of the complex leads to the phosphorylation of Type I receptors by Type II receptors, subsequently triggering the canonical SMAD1/5/8 signaling pathway or various non-canonical pathways like MAPK (PubMed: 32161015). Dysfunctional BMPR signaling is a hallmark of several pathologies; for instance, loss-of-function mutations in BMPR2 are the primary genetic cause of pulmonary arterial hypertension (PAH), while gain-of-function mutations in ACVR1 (ALK2) cause the rare ossification disorder fibrodysplasia ossificans progressiva (PubMed: 27535534). Therapeutic interventions targeting these receptors include ligand traps such as sotatercept, which sequesters ligands to rebalance signaling, and small molecule inhibitors like momelotinib that target the kinase activity of specific Type I receptors (DrugBank: DB11775). Monitoring efficacy often involves measuring downstream SMAD phosphorylation or clinical markers of vascular and bone health.

Other names

BMP receptorBone morphogenetic protein receptor type IBone morphogenetic protein receptor type IIActivin receptor-like kinaseALK receptorSerine/threonine-protein kinase receptorBMPR1BMPR2

Small molecule inhibition of the intracellular serine/threonine kinase domain of Type I receptors, ligand sequestration via fusion proteins (ligand traps) to prevent receptor activation, or monoclonal antibody-mediated antagonism to modulate SMAD-dependent gene transcription.